title: A randomized clinical trial of induction therapy with OKT3 in kidney transplantation.
abstract: A randomized, prospective multicenter trial was conducted to compare the safety and efficacy of OKT3 as an induction therapy with that of conventional immunosuppressive therapy administered to cadaveric renal allograft recipients. Two hundred fifteen patients were treated either with OKT3 plus azathioprine and steroids for 14 days with the delayed addition of cyclosporine on day 11, or with conventional immunosuppression (steroids, azathioprine, and cyclosporine). OKT3 patients had significantly fewer rejection episodes (51% vs. 66%, P = 0.032), a longer time to initial rejection (46 days vs. 8 days, P = 0.001), and fewer rejection episodes per patient (0.82 vs. 1.14, P = 0.014) than conventionally treated patients. Kaplan-Meier estimates of two-year graft and patient survival rates were 84% and 95%, respectively, for the OKT3-treated group, and 75% and 94%, respectively, for the conventionally treated group. Following a subsequent first rejection episode, OKT3 reversed 93% of the rejections in patients receiving OKT3 induction therapy and 94% in patients receiving conventional therapy. Adverse experiences reported during OKT3 induction therapy were similar to those seen when the drug was used for rejection. Following initial exposure, 40.3% of the patients tested were positive for anti-OKT3 antibody, only 6.7% of which were of high titer (1:1000). In the presence of low titer (1:100 or less) antibody, OKT3 was successful in reversing rejection in five of six retreated patients tested. In conclusion, treatment with OKT3 (in combination with azathioprine, steroids, and the delayed addition of cyclosporine) is an effective approach for renal allograft maintenance.
authors.affiliation: Division of Nephrology, Oregon Health Sciences University, Portland 97201.
authors.forename: D J
authors.initials: DJ
authors.lastname: Norman
authors.forename: L
authors.initials: L
authors.lastname: Kahana
authors.forename: F P
authors.initials: FP
authors.lastname: Stuart
authors.forename: J R
authors.initials: JR
authors.lastname: Thistlethwaite
authors.forename: C F
authors.initials: CF
authors.lastname: Shield
authors.forename: A
authors.initials: A
authors.lastname: Monaco
authors.forename: J
authors.initials: J
authors.lastname: Dehlinger
authors.forename: S C
authors.initials: SC
authors.lastname: Wu
authors.forename: A
authors.initials: A
authors.lastname: Van Horn
authors.forename: T P
authors.initials: TP
authors.lastname: Haverty
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000917:Antibody Formation; D001379:Azathioprine / Q000008:administration & dosage; D002648:Child; D016572:Cyclosporine / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D006084:Graft Rejection / Q000276:immunology / Q000517:prevention & control*; D006085:Graft Survival / Q000187:drug effects*; D006801:Humans; D007239:Infections / Q000453:epidemiology; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D009369:Neoplasms / Q000209:etiology; D011446:Prospective Studies; D013386:Succinates / Q000008:administration & dosage; D019802:Succinic Acid; D013997:Time Factors; D014181:Transplantation Immunology / Q000187:drug effects
chemical_list: D016853:Muromonab-CD3; D013386:Succinates; D016572:Cyclosporine; D019802:Succinic Acid; D001379:Azathioprine; D008775:Methylprednisolone